Abstract:
Expression of p-mTOR/p-4EBP1 in Rhabdomyosarcoma and Its Clinical SignificanceGangling TONG, Xiaofei SUN, Zijun ZHEN, Lin LINCorrespondence to: Xiaofei SUN, E- mail: gzsunxf@yahoo.com.cnDepartment of Medical Pediatric Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.Abstract Objective: To detect the expression of p-mTOR and p-4EBP1 in rhabdomyosarcoma and to explore its clinical signifi-cance. Methods: The expression of p-mTOR and p-4EBP1 in 70 cases of rhabdomyosarcoma was detected by SABC immunohisto-chemistry. The correlation of p-mTOR and p-4EBP1 expression with the clinicopathologic characteristics and prognosis of the rhabdo-myosarcoma were analyzed. Results: The expression rates of p-mTOR and p-4EBP1 in rhabdomyosarcoma were 75.7% and 65.7%, re-spectively. p-mTOR expression was positively correlated with p-4EBP1 expression ( P < 0.05 ). The expression of p-mTOR was signifi-cantly correlated with pathological subtypes ( P < 0.05 ). The 3-year overall survival and disease-free survival of patients withoutp-mTOR expression were higher than those of patients with positive p-mTOR expression ( P = 0.001, P = 0.014 ). The expression ofp-4EBP1 was significantly correlated with the size of rhabdomyosarcoma ( P < 0.05 ). The 3-year overall survival and disease-free sur-vival of patients without p-4EBP1 expression were higher than those of patients with positive p-4EBP1 expression ( P = 0.017, P =0.052 ). Univariate analysis showed that p-mTOR, p-4EBP1, stage, pathological subtypes, and tumor size were negative prognostic fac-tors for patients with RMS ( P < 0.05 ). Nevertheless, lymph node metastasis, sex, and age were not associated with prognosis ( P >0.05). Conclusion: p-mTOR and p-4EBP1 are overexpressed in rhabdomyosarcoma and are correlated with clinicopathologic character-istics of rhabdomyosarcoma. p-mTOR expression is correlated with p-4EBP1 expression in rhabdomyosarcoma. The expression ofp-mTOR and p-4EBP1 is a negative prognostic factor for rhabdomyosarcoma.Keywords Rhabdomyosarcoma; p-mTOR; p-4EBP1; Prognosis